+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating whether adding lidocaine to the standard pain management can reduce the total amount of opioids used during severe vaso-occlusive crisis in adults with sickle cell disease. This Phase 3 trial focuses on patients admitted to the Intensive Care Unit due to painful vaso-occlusive crisis or acute chest syndrome related to sickle cell disease, aiming to improve pain control and reduce opioid consumption. Participants are randomly assigned to receive either intravenous lidocaine or a placebo alongside standard care. The lidocaine is given as a bolus dose of 1.5 mgkg over 30 minutes followed immediately by a continuous infusion of 1 mgkgh for 72 hours. The placebo group receives the same volume and infusion schedule using sodium chloride solution. Both treatments are administered through a peripheral or central venous catheter. During the study, participants are closely monitored for opioid use during their ICU stay, pain levels, length of ICU and hospital stay, and any complications related to vaso-occlusive crisis. Researchers also assess quality of life, safety of lidocaine infusion, and rates of readmission within 28 days. The main outcome is opioid consumption expressed in morphine milligram equivalents from randomization until ICU discharge, with follow-up for up to 28 days.

Age: 18Years +All GendersPhase 3
12 locations
I

Actively Recruiting

Healthy Volunteer

Sepsis is a serious condition involving life-threatening organ dysfunction caused by an uncontrolled response to infection, affecting many people worldwide. This research aims to understand how a protein complex called NLRP3 inflammasome activates in blood platelets among different groups of patients with bacterial or viral sepsis, including COVID-19 cases. The study evaluates the role of platelets in the intense inflammation called a cytokine storm seen in sepsis. Participants will be divided into five groups those with leptospirosis, bacterial infections including hospital-acquired infections, viral infections excluding COVID-19, non-infected controls, and patients with COVID-19 previously enrolled in another trial. The study involves one blood sample collection per participant to analyze the activation of the NLRP3 inflammasome. During the study, researchers will measure the activation level of the NLRP3 protein in platelets and use confocal microscopy for detailed analysis. Participants will provide consent, and the study will monitor these markers at the baseline. The overall goal is to better understand platelet involvement in sepsis-related inflammation, with no further treatment or follow-up procedures mentioned. The study is observational and includes adults aged 18 years and older.

Age: 18Years +All Genders
1 location
S

Actively Recruiting

This research aims to evaluate the prevalence of the aortic to radial pressure gradient ATRAP in patients experiencing shock outside of cardiac surgery settings. ATRAP is a condition where the blood pressure measured at the radial artery underestimates the aortic pressure, which can affect up to one-third of patients in cardiac surgery. Known risk factors include small height, previous hypertension, long or difficult surgery, and a radial artery diameter less than 1.8mm. The study focuses on patients in shock who receive vasopressor support and undergo arterial pressure monitoring. Participants will be patients aged 18 years or older who are in shock and receiving vasopressor support at a dose equal to or greater than 0.5 micrograms per kilogram per minute of norepinephrine equivalent for more than 30 minutes. These patients will have invasive arterial pressure monitoring using both a radial arterial catheter and a femoral arterial catheter, as decided by their physician. Non-invasive blood pressure measurements will also be taken on both arms using a tension cuff. The study excludes those in the perioperative period of cardiac surgery and certain protected or restricted individuals. Throughout the study, researchers will measure the pressure differences between radial and femoral arterial pressures to identify ATRAP, defined by a systolic difference of at least 25 mmHg or a mean pressure difference of at least 10 mmHg lasting more than 5 minutes. The primary outcome is the prevalence of ATRAP at the time the femoral arterial catheter is in place. Patients will be assessed shortly after shock onset, within 48 hours, with consent obtained prior to participation. The study will monitor and collect blood pressure data without altering standard care.

Age: 18Years - 99YearsAll Genders
9 locations
P

Actively Recruiting

Researchers are studying the effects of acetylsalicylic acid and atorvastatin on overall survival in patients with castrate-resistant prostate cancer CRPC who are starting first-line treatment. This international, open, phase III trial uses a 2x2 factorial randomized design to evaluate these drugs in addition to the standard care for CRPC. The study aims to understand whether adding these medications can improve survival outcomes for this patient group. Participants are randomly assigned to one of four groups standard of care alone, standard of care plus acetylsalicylic acid 100 mg daily, standard of care plus atorvastatin 80 mg daily, or standard of care plus both acetylsalicylic acid and atorvastatin. These treatments are taken daily alongside the usual care for their cancer. The trial monitors patients over up to 15 years to assess the long-term impact on survival. During the study, participants will be regularly evaluated for overall survival, which is calculated from the date of randomization until death. Researchers will also monitor patients for safety and adherence to the treatments. The trial includes detailed eligibility screening, performance status assessments, and laboratory tests to ensure patients meet the criteria to participate safely. The long follow-up period allows for comprehensive observation of treatment effects and patient outcomes.

Age: 18Years +MALEPhase 3
30 locations